Comparison of 2D- and 3D-culture models as drug-testing platforms in breast cancer

Oncology Reports

Volumn 33, Issue 4, 2015, Pages 1837-1843

  Imamura, Yoshinori ^a   Mukohara, Toru ^a,d   Shimono, Yohei ^a,b   Funakoshi, Yohei ^a   Chayahara, Naoko ^a   Toyoda, Masanori ^a   Kiyota, Naomi ^a   Takao, Shintaro ^c   Kono, Seishi ^c   Nakatsura, Tetsuya ^e   Minami, Hironobu ^a,d  

^a Dept of Internal Medicine   (Japan)

^b Division of Cellular and Molecular Biology   (Japan)

^c KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d KOBE UNIVERSITY HOSPITAL   (Japan)

^e NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

3D culture; Anti apoptosis; Breast cancer

Indexed keywords

CASPASE 3; CASPASE 8; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; KI 67 ANTIGEN; PACLITAXEL; ANTINEOPLASTIC AGENT; CASPASE;

ANTIGEN EXPRESSION; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER PATIENT; CELL HYPOXIA; CELL POPULATION; CELL SIZE; COLONY FORMATION; CONTROLLED STUDY; DNA DAMAGE; DOWN REGULATION; DRUG SENSITIVITY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FLUORESCENCE MICROSCOPY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPHEROID CELL; SUPERNATANT; THREE DIMENSIONAL CANCER CELL CULTURE; TUMOR GROWTH; TWO DIMENSIONAL CANCER CELL CULTURE; WESTERN BLOTTING; BREAST NEOPLASMS; CELL CULTURE TECHNIQUE; DRUG RESISTANCE; FEMALE; METABOLISM; MULTICELLULAR SPHEROID; PROCEDURES; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CASPASES; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; KI-67 ANTIGEN; SPHEROIDS, CELLULAR;

EID: 84924873420     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.3767     Document Type: Article

References (25)

1. Hay M, Thomas DW, Rosenthal J, et al: Clinical development success rates for investigational drugs. Nat Biotechnol 32: 40-51, 2014.
2. Yamada KM and Cukierman E: Modeling tissue morphogenesis and cancer in 3D. Cell 130: 601-610, 2007.
3. Hirschhaeuser F, Menne H, Kunz-Schughart LA, et al: Multicellular tumor spheroids: an underestimated tool is catching up again. J Biotechnol 148: 3-15, 2010.
4. Rimann M and Graf-Hausner U: Synthetic 3D multicellular systems for drug development. Curr Opin Biotechnol 23: 803-809, 2012.
5. Breslin S and O'Driscoll L: Three-dimensional cell culture: the missing link in drug discovery. Drug Discov Today 18: 240-249, 2013.
6. Lovitt CJ, Shelper TB and Avery VM: Advanced cell culture techniques for cancer drug discovery. Biology 3: 345-367, 2014.
7. Weigelt B, Ghajar CM and Bissell MJ: The need for complex 3D culture models to unravel novel pathways and identify accurate biomarkers in breast cancer. Adv Drug Deliv Rev 69-70: 42-51, 2014.
8. Lacroix M and Leclercq G: Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res Treat 83: 249-289, 2004.
9. Nobutani K, Shimono Y, Takai Y, et al: Absence of primary cilia in cell cycle-arrested human breast cancer cells. Genes Cells 19: 141-152, 2014.
10. Gamelin E, Delva R, Jacob J, et al: Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. J Clin Oncol 26: 2099-2105, 2008.
11. Zhang S, Hosaka M, Yoshihara T, et al: Phosphorescent lightemitting iridium complexes serve as a hypoxia-sensing probe for tumor imaging in living animals. Cancer Res 70: 4490-4498, 2010.
12. Rohwer N and Cramer T: Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist Updat 14: 191-201, 2011.
13. Sullivan R and Graham CH: Hypoxia prevents etoposideinduced DNA damage in cancer cells through a mechanism involving hypoxia-inducible factor 1 Mol Cancer Ther 8: 1702-1713, 2009.
14. Flamant L, Notte A, Michiels C, et al: Anti-apoptotic role of HIF-1 and AP-1 in paclitaxel exposed breast cancer cells under hypoxia. Mol Cancer 9: 191, 2010.
15. Karlsson H, Fryknas M, Nygren P, et al: Loss of cancer drug activity in colon cancer HCT-116 cells during spheroid formation in a new 3-D spheroid cell culture system. Exp Cell Res 318: 1577-1585, 2012.
16. Vinci M, Gowan S, Boxall F, et al: Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation. BMC Biol 10: 29, 2012.
17. Lee JM, Mhawech-Fauceglia P, Lee N, et al: A three-dimensional microenvironment alters protein expression and chemosensitivity of epithelial ovarian cancer cells in vitro. Lab Invest 93: 528-542, 2013.
18. No authors listed: Dishing out cancer treatment. Nat Biotechnol 31: 85, 2013.
19. Marangoni E, Vincent-Salomon A, Auger N, et al: A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res 13: 3989-3998, 2007.
20. Cottu P, Marangoni E, Assayag F, et al: Modeling of response to endocrine therapy in a panel of human luminal breast cancer xenografts. Breast Cancer Res Treat 133: 595-606, 2012.
21. Zhang X, Claerhout S, Prat A, et al: A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res 73: 4885-4897, 2013.
22. Fong EL, Martinez M, Yang J, et al: Hydrogel-based 3D model of patient-derived prostate xenograft tumors suitable for drug screening. Mol Pharm 11: 2040-2050, 2014.
23. Housman G, Byler S, Sarkar S, et al: Drug resistance in cancer: an overview. Cancers 6: 1769-1792, 2014.
24. Li J, Shi M, Cao Y, et al: Knockdown of hypoxia-inducible factor-1alpha in breast carcinoma MCF-7 cells results in reduced tumor growth and increased sensitivity to methotrexate. Biochem Biophys Res Commun 342: 1341-1351, 2006.
25. Doublier S, Belisario DC, Sapino A, et al: HIF-1 activation induces doxorubicin resistance in MCF7 3-D spheroids via P-glycoprotein expression: a potential model of the chemoresistance of invasive micropapillary carcinoma of the breast. BMC Cancer 12: 4-18, 2012.